Paul Hudson has been CEO of Sanofi since September. Now this week he will meet with investors and Wall Street analysts to reveal his strategy for the giant French pharmaceutical company.
Prior to the important meeting, Hudson said he has traveled country to country on a "listening tour," talking to Sanofi staff and getting his input.
"Like someone coming in from outside," he said, "i
have an opportunity to have fresh eyes across all sides of
With $ 42 billion in 2018 revenue, Sanofi has more than 100,000 employees and business across the globe as a dominant player in the vaccine market, which also makes medicines to treat diabetes, cancer, blood diseases, asthma and dermatitis. It is ranked on Fortunes list of the world's 500 largest companies.
Hudson has an impressive track record of successful drug product launches. Prior to Sanofi, he led the drug business at Novartis, where he was credited with turning the cardiac Entresto into a blockbuster.
While studying the medicine in Sanofi's medicine cabinet, he says he takes a "dispassionate" and "critical look." Any changes he makes, he says, will depend on a basic question about each drug. "Will anyone be better, transformed and saved by something we have that is unique to us?" He asks.
What is his diagnosis so far? "I've seen some things stay
I'm very excited, "he says enthusiastically.
What market analysts certainly want to hear from Hudson is what he plans to do to get investors excited about the Sanofi stock. It's been flat for the last five years.
" I think it's a story that can be told better about the company, "Hudson says, adding that many people have asked him what the company stands for and where it's headed. He plans to address all of this this week in Boston, and said "I think clarity is overdue."
Watch the video above for more.